The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Ambrilia Biopharma

Monday Biotech Deal Review: April 11, 2011

Welcome to your Monday Biotech Deal Review for April 11, 2011.  Notable events in the Canadian biotech space over the past week included: (i) the filing by Valeant with the SEC of a consent solicitation statement in furtherance of its efforts to replace the board of its hostile target Cephalon; (ii) the approval by creditors of the plan put forward by Angiotech in respect of its restructuring and the sanctioning of the plan by courts in Canada and the U.S.; (iii) the closing of a $34.5M private placement by MethylGene; and (iv) the resignation of the board of directors of Ambrilia and the seeking by Ambrilia to pursue insolvency proceedings under the Bankruptcy statute as opposed to creditor protection under the CCAA.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 4, 2011

Welcome to your Monday Biotech Deal Review for April 4, 2011.  Valeant was a major headline last week with its hostile $5.7 billion leveraged-buyout offer for Cephalon, Inc., which some are suggesting may herald a new era of M&A activity in the biotech sector (you’ll recall that Valeant itself is the product of the recent merger with biotech heavyweight Biovail Corporation).   In addition, CCAA-protected Angiotech has filed a second amended and restated plan of compromise or arrangement and has made amendments to its support agreements, which plan is scheduled to be voted by creditors this week.  Last week continued the previous weeks’ pick-up in financing, with some newly announced and closed private placements.  And to top it off there were also a number of interesting commercial and licensing transactions.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: March 21, 2011

Welcome to your Monday Biotech Deal Review for March 21, 2011.  There was some interesting investment and commercial transactions announced and closed last week, including the $15M private placement announced by Novadaq, the $4M bond financing closed by SemBioSys and Pacgen’s announcement of a corporate makeover to accommodate its recent investments in the products of General Biologicals Corporation.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: March 7, 2011

Welcome to your Monday Biotech Deal Review for March 7, 2011.  It was a busy week with numerous private and public investments, offerings by biotech companies (see Stem Cell Therapeutics and Adherex Technologies), as well as some interesting licensing activity.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: February 21, 2011

Welcome to your Monday Biotech Deal Review for February 21, 2011.  Among other news, Angiotech made some progress this week in CCAA proceedings with respect to its recapitalization, and Merck Canada has made another investment in Quebec’s biopharma sector, investing $6.8M.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: February 7, 2011

Welcome to your Monday Biotech Deal Review for February 7, 2011.  It was a fairly busy week for Canadian biotech – Angiotech has followed suit in the U.S. on the heels of last week’s CCAA filing, a number of acquisitions were announced, and there was some activity in biotech licensing.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 31, 2011

Welcome to your Monday Biotech Deal Review for January 31, 2011.  Angiotech has voluntarily entered into CCAA proceedings and will continue its restructuring efforts there.  There was also some investment activity involving government agencies in Ontario, Quebec and Prince Edward Island.  Read on to learn more, as well as the usual assortment of biotech news reviews from the past week.  Read more of this post

Monday Biotech Deal Review: January 24, 2010

Welcome to your Monday Biotech Deal Review for January 24, 2010.  Despite a slow financing week, there were a few operational announcements as well as awards granted to Canadian biotech companies by the NIH and the UK’s Medical Research Council.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 17, 2011

Welcome to your Monday Biotech Deal Review for January 17, 2011.  Among other things, the past week saw a third extension of deadlines for Angiotech’s debt restructuring efforts, a management-approved take-over bid of WEX Pharmaceuticals, and American DARPA money being spent on Medicago for the development of a H5N1 vaccine.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: January 10, 2011

Welcome to your Monday Biotech Deal Review.  2011 is off to a fast start in Canadian biotech!  Among other things, last week’s highlights included some interesting licensing activity, the completion by Bioniche of its A$12.5 million Australian offering, a $200k SEDA draw-down by Allon Therapeutics, Futuremed’s conversion to a corporation, and some regulatory and litigation updates as well.  Read on to learn more.

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: December 13, 2010

Welcome to your Monday Biotech Deal Review.  It was a bit of a slow week this week, with a few small private placement announcements, and some activity in the licensing sector.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: November 29, 2010



Welcome to your Monday Biotech Deal Review.  I hope our American readers had a very happy thanksgiving weekend, but hopefully there’s still some room left for your weekly digest of biotech deals.  This week witnessed the closing of the US$52M IMRIS financing [Ed. -- as well as a rafter of other deals].  Read on to learn more about these and other deals from the previous week.  Read more of this post

Monday Biotech Deal Review: November 15, 2010

Welcome to the Monday Biotech Deal Review for November 15, 2010.  Read on to learn about IMRIS’ proposed U.S. IPO, a mysterious merger in the making, and heart lasers (and how much they go for), together with your usual assortment of private placements, announcements and other biotech news.  Read more of this post

Monday Deal Review: November 1, 2010

Welcome to the Monday Deal Review for November 1, 2010.  This week’s review contains the news of a possible recapitalization of Angiotech, following its deferral of interest payments on 7.75% Senior Subordinated Notes due October 1, 2010.  Read on to learn more, as well as other happenings from last week’s biotech scene. Read more of this post

Monday Biotech Deal Review: October 18, 2010

Despite the short week, it was a busy one in the Canadian biotech sector. Read on to learn about the Labopharm / Paladin licensing deal, Ondine’s new facelift (and 15:1 equity liposuction), and various other biotech updates and news. 

Read more of this post

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: April 12, 2010

This week deals are back in full force, despite the fact that Tengion’s IPO was less popular than expected and Neovacs scaled back its planned IPO.  Highlights include Patheon raising $280 million from its note placement, Verio Therapeutics getting phagocytosed by Fate (but remaining in Ottawa) and Lorus Therapeutics’ F-1 filing for a $17.5 million unit offering. Read more of this post

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve seen after the jump…

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis and Chattem and Seattle Genetics and GSK.  Check out the past week’s Canadian deal-making (and breaking) after the jump…

Monday Deal Review: August 3, 2009

B&W_BigNickelHopefully, the Deal Review will be a longer list as the newly-launched Ontario Emerging Technologies Fund starts deploying some capital, but for this week, the Canadian deal front was pretty quiet.   A few developments, like the JLL-Patheon pathos and the milestone for Cardiome from Merck, were noted at the time in our Twitter stream @crossborderbio, and aside from that there are only a few deals, and a bit of bad news, to check out  after the jump…

Monday Deal Review: July 27, 2009

B&W_BigNickelWell, July is wrapping up with no sign of summer, or of the summer doldrums.  Read on for all the rainy-day deals we found this week after the jump…

Monday Deal Review: July 20, 2009

B&W_BigNickelThis week’s deal review has some more info about Ambrilia’s deal with Kotinos that I tweeted about at the time (my Twitter stream shows up in the sidebar on the right here), as well as an update on JLL-Patheon and a raft of securities deals, including an issuer bid after the jump…

Follow

Get every new post delivered to your Inbox.

Join 126 other followers